OSE Immunotherapeutics has received global rights to autoimmune disease candidate FR104 from Janssen Biotech.
The drug was licensed to Janssen in September 2013 under a licence agreement, which is planned to be terminated in December 2018.
American biotechnology company Janssen returned the asset following an internal strategic review and product portfolio prioritisation.
OSE Immunotherapeutics is a biotechnology company based in France.
Tango Therapeutics will use Gilead Sciences’ genomics-based discovery platform to discover, develop and commercialise novel immuno-oncology therapies under a new partnership.
Tango Therapeutics will perform target discovery and validation under the multi-year deal while Gilead will have the option to obtain global rights for up to five targets discovered.
Additionally, Tango will hold the option to co-develop and co-detail two candidates in the US.
Gilead will make an upfront payment of $50m to Tango, with Tango also eligible to receive up to $1.7bn in the form of milestone payments and royalties.
Both companies are biotechnology firms based in the US.
Provention Bio will develop Amgen’s drug candidate, AMG 714, under a licensing and co-development agreement.
AMG 714 is being developed to treat gluten-free diet non-responsive celiac disease (NRCD).
Provention Bio will perform a Phase IIb clinical study and rename the drug PRV-015. It will also be responsible for further development and related regulatory processes, while Amgen will manufacture the drug.
Amgen will make an investment of $20m in Provention Bio as part of the transaction. Provention will be eligible to receive $150m as a milestone, as well as other potential royalties and payments following the completion of the Phase IIb trial.
Provention Bio is a clinical-stage biopharmaceutical company, while Amgen is a biotechnology company. Both companies are based in the US.
Sementis has partnered with Enesi Pharma to develop potential vaccine candidates for the treatment of peanut allergy and chikungunya or Zika infection.
Enesi’s ImplaVax needle-free implant and device technology will be utilised to develop and assess solid dose variants of Sementis’ peanut hypo allergy vaccine and chikungunya and Zika vaccine candidates.
Sementis will perform the safety and immunogenicity testing and pre-clinical development of the drugs.
Based in Australia, Sementis is a biotechnology company, while Enesi Pharma is a British pharmaceutical company.
Denali Therapeutics has collaborated with Sanofi to further the development of therapies for neurological and systemic inflammatory diseases under a deal worth more than $1bn.
The two companies will advance the development of the DNL747 and DNL758 molecules.
Denali will perform Phase II studies on DNL747 for Alzheimer’s disease, while Sanofi will perform Phase II studies on DNL747 for multiple sclerosis and amyotrophic lateral sclerosis. Sanofi also plans to conduct Phase III trials in the future.
Sanofi will make an upfront payment of $125m to Denali, which will also be eligible to receive up to $1bn in milestone payments.
Denali Therapeutics is an American biotechnology company, while Sanofi is a pharmaceutical company based in France.